The ductus arteriosus (DA) is a muscular fetal artery connecting the pulmonary and systemic circulations. In utero, elevated pulmonary vascular resistance coupled with relatively low systemic resistance promotes right-to-left blood flow through the DA, allowing blood oxygenated by the placenta to bypass the developing lungs. 1 Postnatally, the DA must close to allow appropriate perfusion of the newly inflated lungs. Failure of this vessel to close within the first few days of life results in a persistent left-to-right shunt termed patent ductus arteriosus (PDA). PDA disproportionately affects premature infants (with a reported incidence of up to 80% in infants < 1000 grams) 2 and accounts for 5%-10% of all congenital heart defects in term infants. 3 Consequences of prolonged DA patency include: (1) overcirculation of the lungs due to excessive left-to-right shunt; (2) left-sided heart enlargement due to the increased blood volume returning from the lungs; and (3) ductus "steal" phenomenon resulting in decreased perfusion of peripheral organs. Therefore, PDA is associated with significant morbidities, including congestive heart failure, necrotizing enterocolitis, spontaneous intestinal perforation, neurodevelopmental impairment, intraventricular hemorrhage, respiratory distress syndrome, and chronic lung disease.
| INTRODUC TI ON
The ductus arteriosus (DA) is a muscular fetal artery connecting the pulmonary and systemic circulations. In utero, elevated pulmonary vascular resistance coupled with relatively low systemic resistance promotes right-to-left blood flow through the DA, allowing blood oxygenated by the placenta to bypass the developing lungs. 1 Postnatally, the DA must close to allow appropriate perfusion of the newly inflated lungs. Failure of this vessel to close within the first few days of life results in a persistent left-to-right shunt termed patent ductus arteriosus (PDA). PDA disproportionately affects premature infants (with a reported incidence of up to 80% in infants < 1000 grams) 2 and accounts for 5%-10% of all congenital heart defects in term infants. 3 Consequences of prolonged DA patency include: (1) overcirculation of the lungs due to excessive left-to-right shunt; (2) left-sided heart enlargement due to the increased blood volume returning from the lungs; and (3) ductus "steal" phenomenon resulting in decreased perfusion of peripheral organs. Therefore, PDA is associated with significant morbidities, including congestive heart failure, necrotizing enterocolitis, spontaneous intestinal perforation, neurodevelopmental impairment, intraventricular hemorrhage, respiratory distress syndrome, and chronic lung disease. 4 The DA is a deceptively complex vessel that has challenged clinicians and basic scientists for centuries. Anatomical descriptions of the ductus date back to the second century AD, 5 however, the first illustrations of the DA didn't appear until the mid-1600s. The
English physician, Sir William Harvey recognized its importance in fetal circulation and more accurately described the fetal DA as two roots of the great artery stemming from the heart that withers after birth. 6 Over the next three centuries, seminal studies by Jager and Wollenman, Cassels, Gittenberger-de Groot, and many others provided a detailed analysis of the DA's distinct histological structure. [7] [8] [9] Their observations describe the fetal DA as a muscular artery with a "looser" structure than the aorta or pulmonary artery, containing an internal elastic lamina but devoid of elastic fibers in the tunica media.
In contrast, the mature DA poised for closure is said to contain spiral arrangements of smooth muscle fibers, a fragmented internal elastic lamina, and increasing numbers of intimal cushions composed of medial cells protruding into the vessel lumen, while a persistently patent term-gestation vessel contains thickened intact elastic laminae and/or ectopic elastic fibers and lack intimal cushions. 10, 11 Similarly, hallmark studies by Coceani and Olley, 12 Elliott, 13 Sharpe, 14 Kennedy and Clark, 15 and Clyman 16 among others gave us the first mechanistic insights into the role of prostaglandins and oxygen in regulation of DA tone. And yet, even with the aid of cutting-edge molecular biology techniques and major advances in diagnostics and patient management, the DA remains somewhat of a developmental enigma and questions regarding the genetic predisposition to PDA or its treatments, the timing of spontaneous closure, and best pharmacologic strategies for the persistently patent DA still remain. 17 
| FAC TOR S REG UL ATING DUC TUS TONE IN UTERO
The fetal DA has intrinsic tone and requires dilating factors to counteract competing vasoconstrictive agents in order to maintain patency in utero ( Figure 1) . Patency of the preterm DA is maintained by nitric oxide (NO) signaling, while that burden shifts to prostaglandin E 2 (PGE 2 ) later in development. 18 NO signaling relaxes the DA by activating cGMP/PKG signaling. PGE 2 , working primarily through the EP4 receptor, induces DA dilation via activation of cAMP/PKA. While NO and PGE 2 are typically considered the primary mediators of DA dilation, other factors clearly play a role. Adenosine 19 and atrial naturetic peptide 20 have both been shown to dilate the DA via up-regulation of cAMP and cGMP signaling, respectively. Moreover, the gasotransmitter carbon monoxide (CO) also acts as a cGMP-mediated vasodilator 21 and elevated levels of endogenously produced CO (as measured by end-tidal CO, corrected for CO in ambient air) has been associated with symptomatic PDA in preterm infants. 22 In addition, voltage-gated potassium channels (Kv1.5, Kv 1.2, Kv2.1), ATP-gated potassium (K ATP ) channels, and larger-conductance voltage-dependent and calcium-activated potassium (BK Ca ) channels are enriched in the DA and act as vasodilators upon activation.
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| FAC TOR S MED IATING DUC TUS CONTR AC TI ON AF TER B IRTH
Over the years, many hypotheses have been put forth to explain the mechanism of postnatal DA closure. Early investigators postulated 2 , prostaglandin E2, ROS, reactive oxygen species; TP, thromboxane receptor that the DA became kinked, compressed, or elongated to the point of vessel collapse after birth, resulting in an interruption of blood flow and thrombus formation. 6 However, these suppositions were all based on examination of postmortem tissue. Later histological studies suggested closure by active muscular contraction. 8 Our current understanding of postnatal DA constriction is that smooth muscle cell contraction is triggered by two major events: a precipitous decrease in PGE 2 levels and the onset of ventilation (Figure 1 ).
Prostaglandin-induced DA relaxation is interrupted by umbilical cord clamping and removal of the placenta, thereby eliminating a major source of circulating prostaglandins. In addition, the onset of postnatal respiration reduces pulmonary vascular resistance and increases blood flow to the lungs (Figure 2) , where prostaglandins are metabolized by 15-hydroxyprostaglandin dehydrogenase, further precipitating their decline.
DA closure is simultaneously initiated by the onset of respiration.
A neonate's first few breaths serve to drive out fetal lung liquid from the alveolar space, allowing pulmonary gas exchange to commence, resulting in increased oxygen tension. 25 Crying (in which a large inspiration is followed by a forced expiration) immediately after birth has been hypothesized to aid in liquid clearance from the lung and cardiovascular transition. 26 Indeed, one study found that infants who cried more often within the first 10 minutes after birth had a lower DA flow ratio (right-to-left:left-to-right) and increased left ventricular output, signifying a faster neonatal transition. 27 Appreciating the relationship between respiration and DA constriction, Kennedy and Clark performed some of the earliest mechanistic studies in the early 1940s, noting that oxygen, but not nitrogen, could induce DA closure. 15 Moreover, Born et al demonstrated that ventilation of pregnant sheep with 100% oxygen caused increased fetal carotid oxygen saturation and corresponding DA constriction. of endothelin-1, production of "constrictor" isoprostanes (8-iso-PGF2α), and mitochondrial-mediated reactive oxygen species inhibition of Kv1.5 and Kv2.1. 4 Oxygen can also inhibit K ATP channels resulting in membrane depolarization and activation of voltage-dependent calcium channels. 29 Other factors including the transient receptor potential channel, TRPM3, 30 angiotensin II, and Rho kinase family members (RhoA/B, Rock1/2) also promote DA constriction (Figure 1 ). In addition, the DA is innervated with cholinergic and adrenergic nerves that mediate constriction in response to acetylcholine and norepinephrine. 19 Despite their diversity, all of these pathways eventually converge on Ca 2+ -mediated phosphorylation of myosin light chain, leading to actin/myosin interaction and ultimately DA smooth muscle cell contraction. in cases where the preterm duct does close without intervention, the time to closure is inversely proportional to gestational age at birth, with some very low birth weight infants requiring months or even years to achieve closure. 34, 35 Given that prolonged left-toright shunting has been associated with multiple morbidities, a more comprehensive understanding of factors that regulate the timing of DA closure (beyond oxygen and prostaglandins) and the molecular consequences of altered hemodynamic forces is needed to resolve which PDAs require intervention and which ones can safely be left to close on their own. 
| CON CLUS ION
Persistent patency of the DA has been recognized for nearly two millennia. The longstanding association of PDA with adverse neonatal outcomes has led physicians to seek curative treatments to induce DA closure. Understanding the molecular and biomechanical forces that maintain relaxation of the fetal DA and orchestrate its closure after birth will support the development of novel treatments or provide a rational basis for tolerating its ongoing patency when conservative management strategies might be optimal.
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